Hobo Medicine - B (02142.HK): Enkesai Medicine has completed Series A+++ financing, raising nearly 100 million yuan.

Chinatong Financial News App learns that Po Medicine-B (02142.HK) announced that the company's invested company Shanghai Enkai Cell Technology Co., Ltd. (Enkai Sai Drug) has recently completed a Series A+++ financing round, this round of financing was participated by multiple investors, raising nearly 100 million yuan. The funds raised will be used to advance its core NK cell therapy product candidate through clinical trials and support the development of its product pipeline.